SCHOTT Pharma AG & Co KgaA (1SXP) Stock Price & News

1SXP:ETR

SCHOTT Pharma AG & Co KgaA

€23.50

-4.67%

(-1.15) 1D

Oct 9, 5:35:12 PM GMT+2 · EUR

All symbols

	Symbol	Price	Change	% Change

Last report

Aug 12, 2026

Fiscal period

Q3 2026

€0.26 / €0.26

-1.81%miss

Revenue / Est. (EUR)

281.76M / 272.46M

+3.41%beat

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance

Insights from the latest news and reports

Previous reportsAll values in EUR

Loading Previous Earnings...

All values in EUR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	247.58M	240.19M	247.88M	281.76M
Cost of goods sold	171.50M	160.44M	172.78M	195.38M
Cost of revenue	171.50M	160.44M	172.78M	195.38M
Research and development expenses	6.36M	7.34M	6.05M	6.34M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	32.89M	33.73M	32.51M	35.30M
Operating expense	35.95M	40.70M	35.55M	37.48M
Total operating expenses	207.45M	201.14M	208.33M	232.86M
Operating income	40.14M	39.05M	39.55M	48.90M
Other non operating income	-61.00K	-79.00K	-212.00K	-116.00K
EBT including unusual items	41.76M	42.04M	40.31M	51.23M
EBT excluding unusual items	41.02M	42.04M	40.31M	51.23M
Income tax expense	8.09M	8.76M	9.17M	12.25M
Effective tax rate	19.37%	20.84%	22.76%	23.91%
Other operating expenses	-3.30M	-366.00K	-3.01M	-4.16M
Net income	33.56M	33.18M	31.01M	38.83M
Net profit margin	13.55%	13.81%	12.51%	13.78%
Earnings per share	0.22	0.22	0.21	0.26
Interest and investment income	2.02M	2.33M	1.84M	1.96M
Interest expense	-4.71M	-4.00M	-4.01M	-3.87M
Net interest expenses	-2.69M	-1.67M	-2.16M	-1.91M
Depreciation and amortization charges	-	-	-	-
EBITDA	56.70M	60.46M	61.41M	71.14M
Gain or loss from assets sale	-88.00K	-48.00K	-72.00K	48.00K

Finance